Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
42 studies found for:    "Cutaneous lupus erythematosus"
Show Display Options
Rank Status Study
1 Completed Treatment of Cutaneous Lupus Erythematosus (CLE) With the 595 nm Flashlamp Pulsed Dye Laser
Condition: Cutaneous Lupus Erythematosus
Intervention: Procedure: laser treatment (Candela Vbeam Perfecta™)
2 Terminated A Multiple Dose Study Of PD-0360324 In Patients With Active Cutaneous Lupus Erythematosus
Condition: Cutaneous Lupus Erythematosus
Interventions: Drug: PD-0360324;   Drug: Placebo
3 Completed Efficacy of Topical Tacrolimus in Different Subtypes With Cutaneous Lupus Erythematosus (CLE)
Condition: Cutaneous Lupus Erythematosus
Intervention: Drug: Tacrolimus ointment
4 Recruiting Prevalence and Clinical Severity of Cutaneous Lupus Erythematosus
Condition: Cutaneous Lupus Erythematosus
Intervention:
5 Completed
Has Results
IVIg Efficacy Study to Treat Cutaneous Lupus Erythematosus
Condition: Cutaneous Lupus Erythematosus
Intervention: Drug: IVIg
6 Completed Sunscreens in Patients With Cutaneous Lupus Erythematosus(CLE)
Condition: Cutaneous Lupus Erythematosus
Intervention: Other: UV A and B irradiation
7 Completed
Has Results
Effectiveness of a Knowledge-based Intervention for Patients With Cutaneous Lupus Erythematosus
Condition: Cutaneous Lupus Erythematosus
Intervention: Behavioral: Cutaneous Lupus educational script
8 Completed To Evaluate the Preliminary Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of CC-11050 in Subjects With Discoid Lupus Erythematosus and Subacute Cutaneous Lupus Erythematosus
Condition: Cutaneous Lupus Erythematosus
Interventions: Drug: CC-11050;   Other: Placebo
9 Completed Safety and Efficacy of KRP203 in Subacute Cutaneous Lupus Erythematosus
Condition: Subacute Cutaneous Lupus Erythematosus
Interventions: Drug: KRP203 - 1.2mg;   Drug: Placebo to KRP203 - 1.2 mg
10 Completed Evaluation of Lenalidomide (REVLIMID®) to Treat Subjects With Cutaneous Lupus Erythematosus (CLE)
Condition: Cutaneous Lupus Erythematosus (CLE)
Intervention: Drug: lenalidomide (Revlimid®)
11 Completed Multicenter Study Assessing the Efficacy & Safety of Hydroxychloroquine Sulfate in Patients With Systemic Lupus Erythematosus or Cutaneous Lupus Erythematosus With Active Lupus Erythematosus Specific Skin Lesion
Condition: Cutaneous Lupus Erythematosus-Systemic Lupus Erythematosus
Interventions: Drug: hydroxychloroquine (Z0188);   Drug: Placebo
12 Terminated Efficacy and Safety of Oral Alitretinoin (Toctino®) in the Treatment of Patients With Cutaneous Lupus Erythematosus
Condition: Lupus Erythematosus, Cutaneous
Intervention: Drug: Alitretinoin
13 Not yet recruiting Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Clinical Effect of GSK2646264 in Cutaneous Lupus Erythematosus Patients
Condition: Lupus Erythematosus, Cutaneous
Interventions: Drug: GSK2646264 1%;   Drug: Placebo
14 Completed Efficacy and Safety of Fumaric Acid Esters (Fumaderm®) in the Treatment of Patients With Cutaneous Lupus Erythematosus
Condition: Lupus Erythematosus, Cutaneous
Intervention: Drug: Fumaric acid esters
15 Unknown  Cutaneous Lupus Erythematosus and Elidel
Conditions: Lupus Erythematosus, Cutaneous;   Lupus Erythematosus, Discoid
Intervention: Drug: Elidel (pimecrolimus)
16 Enrolling by invitation European Society of Cutaneous Lupus Erythematosus (EUSCLE)
Conditions: Lupus Erythematosus, Cutaneous;   Lupus Erythematosus, Systemic
Intervention: Procedure: laboratory analysis
17 Completed A Study of the Safety and Pharmacokinetics of CNTO 136 in Patients With Cutaneous Lupus Erythematosus and Systemic Lupus Erythematosus
Conditions: Lupus Erythematosus, Cutaneous;   Lupus Erythematosus, Systemic
Interventions: Drug: 1 mg/kg CNTO 136;   Drug: 4 mg/kg CNTO 136;   Drug: 10 mg/kg CNTO 136;   Drug: Placebo
18 Terminated Vitamin D Status, Disease Specific and Quality of Life Outcomes in Patients With Cutaneous Lupus
Condition: Cutaneous Lupus Erythematosus
Intervention: Dietary Supplement: vitamin D
19 Recruiting Study to Evaluate BIIB059 in CLE With or Without SLE
Conditions: Systemic Lupus Erythematosus (SLE);   Active Cutaneous Lupus Erythematosus (CLE)
Interventions: Drug: BIIB059;   Drug: Placebo
20 Recruiting Low-dose UVA1 Radiation in Cutaneous Lupus Patients
Condition: Cutaneous Lupus Erythematosus
Intervention: Device: UVA1 radiation treatment

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.